Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial

Journal of Infectious Diseases

Volumn 206, Issue 6, 2012, Pages 961-968

  Labarga, Pablo ^a   Barreiro, Pablo ^a   Da Silva, Alfredo ^e   Guardiola, Josep María ^g   Rubio, Rafael ^b   Aguirrebengoa, Koldo ^h   Miralles, Pilar ^c   Portu, Joseba ⁱ   Téllez, Maria Jesús ^d   Morano, Luis ^f   Castro, Ángeles ^j   Pineda, Juan Antonio ^k   Terrón, Alberto ^m   Hernández Quero, José ⁿ   Mariño, Ana ^o   Ríos, Maria José ^l   Echeverría, Santiago ^p   Asensi, Víctor ^q   Vispo, Eugenia ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL XERAL CÍES   (Spain)

^f HOSPITAL DO MEIXOEIRO   (Spain)

^g HOSPITAL SANT PAU   (Spain)

^h HOSPITAL DE CRUCES   (Spain)

ⁱ HOSPITAL TXAGORRITXU   (Spain)

^j HOSPITAL JUAN CANALEJO   (Spain)

^k HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^m HOSPITAL DE JEREZ   (Spain)

ⁿ HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^o Servicio de Medicina Interna   (Spain)

^p HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^q HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IL28B GENE; INDUCTION CHEMOTHERAPY; INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIXED INFECTION; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RESPIRATORY TRACT INFECTION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL;

EID: 84865753312     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis449     Document Type: Article

References (34)

1. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-89.
2. Weber R, Sabin C, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-41.
3. Chung R, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
4. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIVinfected patients. N Engl J Med 2004; 351:438-50.
5. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIVinfected patients. JAMA 2004; 292:2839-48.
6. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27-36.
7. Núñez M, Miralles C, Berdún M, for the PRESCO Study Group. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients. AIDS Res Hum Retroviruses 2007; 23:972-82.
8. Manns M, McHutchison J, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
9. Fried M, Shiffman M, Reddy K, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
10. Brady D, Torres D, An J, et al. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, openlabel study. Clin Gastroenterol Hepatol 2010; 8:66-7.
11. Tural C, Solà R, Rubio R, et al. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study. J Viral Hepat 2007; 140:704-13.
12. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41:275-9.
13. Núñez M, Ocampo A, Aguirrebengoa K, the PRESCO Team. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. J Viral Hepat 2008; 15:363-9.
14. Nuñez M, Camino N, Ramos B, et al. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther 2005; 10:657-62.
15. Maynard M, Pradat P, Gagnieu M, et al. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 2008; 13:607-11.
16. Rendon A, Nuñez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virological response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005; 39:401-5.
17. Dixit N, Layden-Almer J, Layden T, Perelson A. Modeling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432:922-4.
18. Soriano V, Sherman K, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus coinfected patients. AIDS 2011; 25:2197-208.
19. Rockstroh J, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-8.
20. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009; 4:e8209.
21. Morello J, Rodriguez-Novoa S, Cantillano A, et al. Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. Ther Drug Monit 2007; 29:802-6.
22. Ziol M, Handra-Luca A, Kettaneh A, et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41:48-54.
23. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
24. de Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41: 175-9.
25. Vergara S, Macías J, Rivero A, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C coinfection. Clin Infect Dis 2007; 45:969-74.
26. Kirk G, Astemborski J, Mehta S, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009; 48:963-72.
27. Livak K. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999; 14:143-9.
28. Medrano J, Neukam K, Rallon N, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010; 51:1209-16.
29. European AIDS Clinical Society (EACS) guidelines. Updated October 2011. www.europeanaidsclinicalsociety.org/guid/index.html?b=annex. Accessed on 8 February 2012.
30. Saito H, Tada S, Ebinuma H, et al. Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. J Clin Microbiol 2006; 44:3562-8.
31. Morello J, Cuenca L, Soriano V, et al. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. J Infect Dis 2010; 202:1185-91.
32. Baiocchi L, de Leonardis F, delle Monache M, et al. Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response. Antivir Ther 2010; 15:633-9.
33. Sulkowski M, Shiffman M, Afdhal N, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virological response rate. Gastroenterology 2010; 139:1602-11.
34. Sievert W, Dore G, McCaughan G, et al. Virological response is associated with decline in hemoglobin concentrations during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology 2011; 53:1109-17.